Alpha-Adrenergic Modulators for Neuropathic Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropathic pain are inadequate, often resulting in persistent pain and severe side effects such as sedation and addiction, with no available drugs providing long-term relief without significant adverse effects.
Innovation Solution
Development of α-adrenergic modulator compounds, specifically N-(2 and/or 3-substituted benzyl)-4,5-dihydro-1H-imidazol-2-amine, which activate α2A and/or α2C adrenergic receptors to provide analgesic effects with minimal sedation and cardiovascular depression, allowing for oral administration and prolonged pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current analgesic therapies are used to treat neuropathic pain, then pain relief is achieved, but severe side effects such as sedation, cognitive changes, and addiction occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of α-adrenergic agonists to create compounds with altered pharmacological properties. The specific structural modifications (substituting hydrophobic groups at positions 1 and 2 of the benzene ring) change the drug's interaction with receptors, providing pain relief while reducing sedative and addictive side effects.
Solution Approach 2:
The patent applies local quality by making specific localized modifications to the molecular structure of the drug compound. By substituting particular groups at specific positions (1 and 2) of the benzene ring while leaving other parts of the molecule unchanged, the invention achieves selective modification of pharmacological effects - maintaining analgesic activity while reducing unwanted central nervous system effects.
2Reliability
If α2 adrenergic agonists are administered orally, then pain relief is provided, but sedation and hypotension occur
Solution Approach 1:
The patent modifies physical-chemical parameters of the drug molecule through specific structural substitutions. By introducing hydrophobic groups at positions 1 and 2 of the benzene ring, the compound's pharmacokinetic and pharmacodynamic properties are altered, enabling oral administration with reduced central nervous system penetration and thus less sedation and hypotension.
Solution Approach 2:
The patent creates a modified version (copy) of the α-adrenergic agonist structure that retains the essential pharmacological activity. The core imidazoline structure is preserved and copied, while specific benzene ring substituents are modified to achieve the desired profile of reduced side effects while maintaining analgesic efficacy.
3Duration of action of moving object
If conventional analgesics are administered frequently, then pain symptoms are temporarily alleviated, but no long-term cure is achieved and dependency develops
Solution Approach 1:
The patent changes the temporal parameter of drug action through structural modification. The modified α-adrenergic agonists demonstrate prolonged duration of action and sustained analgesic effect, reducing the need for frequent dosing and thereby minimizing the development of dependency while providing longer-lasting pain relief.
Data Source
AI summary
Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.